Hematologic Malignancies Program

Program Leaders: Edward Stadtmauer, MD and Nancy Speck, PhD

The Hematologic Malignancies Program was established in 1994 to translate basic scientific discoveries into novel therapeutics for patients with myeloid and lymphoid neoplasms. The Program has two scientific aims. They are to: 1) develop a mechanisms-based understanding of the genetic, cellular, and biochemical processes regulating normal and malignant hematopoiesis, and 2) translate basic scientific discoveries into more effective and manageable therapies. Thematic areas include transcriptional, translational, and epigenetic regulation of normal and malignant hematopoietic cells; signal transduction in normal and malignant hematopoietic cells; molecular therapeutics; hematopoietic stem cell biology and transplantation; and immune-based therapies.

Hematologic Malignancies Program Membership

Craig Bassing, PhD

Gerd Blobel, MD, PhD

Martin Carroll, MD

Sara Cherry, PhD

Adam Cohen, MD

Kojo Elenitoba-Johnson, MD

Robert Faryabi, PhD, MSc

Carolyn Felix, MD

Noelle Frey, MD, MSCE

Elizabeth Hexner, MD, MSTR

Stephen Liebhaber, MD

Megan Lim, MD, PhD

Selina Luger, MD

Sunita Nasta, MD, FACP

David Porter, MD

David Roth, MD, PhD

Stephen Schuster, MD

Nancy Speck, PhD

Edward Stadtmauer, MD

Jakub Svoboda, MD

Wei Tong, PhD

Dan Vogl, MD, MSCE

Mariusz Wasik, MD

Brendan Weiss, MD